Keyword: BioLineRx

Cancer

BioLineRx jumps then slumps on PhIII data

Shares in BioLineRx went on a brief roller-coaster ride following the release of Phase II data, popping by 16% in premarket trading before dropping a similar amount once the day began proper. The seesawing stock price was triggered by a press release about BioLineRx's Phase II acute myeloid leukemia study, in which the company called the trial a success but presented little data.